Kadimastem’s cell therapy candidate, AstroRx, significantly lowers the rate of disease progression in people with amyotrophic lateral sclerosis (ALS) for at least three months after treatment, updated findings from the company’s Phase 1/2 clinical trial shows. More info here -
https://alsnewstoday.com/2020/08/05/...aign=OneSignal

https://alsnewstoday.com/stem-cell-g...r-als/astrorx/